文献速递肿瘤 PET/CT骨显像与常规 SPECT

基于iPSA与ISUP分级选择前列腺癌初诊分期[99mTc]Tc-PSMA SPECT/CT患者

Patient selection for primary staging with [99mTc]Tc-PSMA SPECT/CT: influence of combined PSA and ISUP grade on detection of metastatic disease.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-09-09

该回顾性研究分析91例前列腺癌初诊分期患者,行[99mTc]Tc-MIP-1404 SPECT/CT,发现iPSA与ISUP分级均为转移性疾病的独立预测因子。ISUP 1-3级且iPSA>50 ng/ml、ISUP 4-5级且iPSA>20 ng/ml时检出率≥50%,且转移播散模式随两者变化。

要点

  • iPSA与ISUP分级均为转移的独立预测因子(pPSA=0.0004,pISUP=0.0015)。
  • ISUP 1-3级且iPSA>50 ng/ml、ISUP 4-5级且iPSA>20 ng/ml时检出率≥50%。
  • iPSA>50 ng/ml者无论ISUP分级均检出转移,且远处转移多见于ISUP 4-5级伴iPSA>50 ng/ml。

核心结论

  • 结合ISUP分级与iPSA可优化[99mTc]Tc-PSMA SPECT/CT初诊分期的患者选择,尤其ISUP 4-5级且iPSA>20 ng/ml和ISUP 1-3级且iPSA>50 ng/ml。
  • 在PSMA PET/CT不可及时,[99mTc]Tc-PSMA SPECT/CT可作为选定前列腺癌患者初诊分期的有价值替代。

研究设计与样本

  • 回顾性研究,91例前列腺癌初诊分期患者接受[99mTc]Tc-MIP-1404 SPECT/CT,给药活度670 MBq(范围470-792 MBq)。
  • 采用单因素及多因素名义逻辑回归分析转移性疾病的预测因素。

主要发现

  • iPSA与ISUP分级均为转移性疾病的独立预测因子(pPSA=0.0004,pISUP=0.0015)。
  • SUVmax与ISUP分级强相关(r=0.61),但不是可靠的替代标志物。
  • ISUP 1-3级且iPSA>50 ng/ml和ISUP 4-5级且iPSA>20 ng/ml时检出率≥50%。
  • iPSA>50 ng/ml者无论ISUP分级均检出转移。
  • 盆腔淋巴结转移在ISUP 1-3级各iPSA水平及ISUP 4-5级且iPSA≤20 ng/ml时占主导;远处转移在ISUP 4-5级且iPSA>50 ng/ml时更常见。

关键数值与推荐

  • 推荐选择ISUP 4-5级且iPSA>20 ng/ml或ISUP 1-3级且iPSA>50 ng/ml的患者行[99mTc]Tc-PSMA SPECT/CT初诊分期。
  • iPSA>50 ng/ml者无论ISUP分级均建议行SPECT/CT以检出转移。

临床怎么用

  • 初诊分期前综合iPSA与ISUP分级筛选适合[99mTc]Tc-PSMA SPECT/CT的患者,避免低风险者过度检查。
  • ISUP 4-5级且iPSA>50 ng/ml者警惕远处转移,ISUP 1-3级或iPSA≤20 ng/ml者以盆腔淋巴结转移为主。
  • PSMA PET/CT不可及时,可按上述标准选用[99mTc]Tc-PSMA SPECT/CT替代。

局限性

  • 回顾性研究,样本量91例,可能存在选择偏倚。
  • SUVmax与ISUP分级虽强相关但非可靠替代标志物,需结合其他影像生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The aim of this study was to examine the combined influence of initial PSA level (iPSA) and ISUP grade on the detection rates of [99mTc]Tc-PSMA SPECT/CT in patients undergoing primary staging of prostate cancer and to identify selection criteria. PATIENTS AND METHODS: In this retrospective study, 91 patients underwent SPECT/CT following administration of 670 MBq (range, 470-792 MBq) [99mTc]Tc-MIP-1404. Detection rates of the primary tumour, pelvic lymph node metastases and distant metastases were determined together with imaging biomarkers. Univariate and multivariate nominal logistic regression analyses identified predictors of metastatic disease. RESULTS: Both iPSA level and ISUP grade were independent predictors of metastatic disease (pPSA=0.0004, pISUP=0.0015). SUVmax correlated strongly with ISUP grade (r = 0.61) but was not a reliable surrogate marker. Detection rates ≥ 50% were observed at ISUP grades 1-3 with iPSA > 50 ng/ml and at ISUP grades 4-5 with iPSA > 20 ng/ml. Metastases were detected in all patients with iPSA > 50 ng/ml, regardless of ISUP grade. Pelvic lymph node metastases predominated at ISUP grades 1-3 across all iPSA and at ISUP grades 4-5 with iPSA ≤ 20ng/ml. Conversely, distant metastases were more frequent at ISUP grades 4-5 with initial PSA > 50ng/ml. CONCLUSION: Patient selection for [99mTc]Tc-PSMA SPECT/CT may be improved by incorporating ISUP grade and iPSA, particularly ISUP grades 4-5 with iPSA > 20 ng/ml and ISUP grades 1-3 with iPSA > 50 ng/ml. Distinct patterns of metastatic spread were observed according to both ISUP grade and iPSA. Where PSMA PET/CT is unavailable, [99mTc]Tc-PSMA SPECT/CT may represent a valuable alternative for primary staging of selected patients with PCa.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Liepe K, Hoang TM, Dietrich I, et al. Patient selection for primary staging with [99mTc]Tc-PSMA SPECT/CT: influence of combined PSA and ISUP grade on detection of metastatic disease. Eur J Nucl Med Mol Imaging. 2026. PMID: 42711500. doi:10.1007/s00259-026-08168-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。